TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT06699771

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing GCC2005, Cyclophosphamide, and other medications for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 19 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

GCC2005 (DRUG): CAR-NK Cell Therapy | Cyclophosphamide (DRUG): Lymphodepleting chemotherapy | Fludarabine (DRUG): Lymphodepleting chemotherapy

Drugs / treatments
GCC2005, Cyclophosphamide, Fludarabine
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

NCT06699771

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing GCC2005, Cyclophosphamide, and other medications for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 19 Years to 80 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

GCC2005 (DRUG): CAR-NK Cell Therapy | Cyclophosphamide (DRUG): Lymphodepleting chemotherapy | Fludarabine (DRUG): Lymphodepleting chemotherapy

Drugs / treatments: GCC2005, Cyclophosphamide, Fludarabine

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 48 patients

Primary endpoint: Safety: Frequency, severity, and persistence of AEs and AEs Grade 3 or higher; To determine MTD and RP2D: Safety(based on frequency, severity, and persistence of AEs and AEs Grade 3 or higher), efficacy (based on ORR) and pharmacokinetics

Ages: 19 Years to 80 Years

Start date: 2025-03-07 | Est. completion: 2027-08

Locations

0 US sites · 3 total

Contact

HyeSung Jeon | hs_jeon@gccorp.com | +82-31-260-9059

Sponsor: GC Cell Corporation (INDUSTRY)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06699771

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.